Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics

CRISPR Therapeutics

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company's Executive Vice President and Chief People Officer. Ms. Aspesi will lead Editas' human resources department and the Company's people strategy in support of its mission and goals.

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

If EDIT-101 continues to show positive results, it has the potential to become the first-ever gene-editing therapy approved for a genetic disease. Editas has established collaborations with leading biopharmaceutical companies, including Bristol Myers Squibb and Juno Therapeutics, to develop innovative gene-editing therapies for a range of diseases.

Editas: The Potential Of Gene Editing Technology And The Risks Of A Lackluster Pipeline

Editas (EDIT) reports a wider loss in the fourth quarter of 2022. The strategic reprioritization, announced last month, is expected to extend the company's cash runway into 2025.

Editas (EDIT) Q4 Earnings Miss Estimates, Pipeline in Focus

Editas Medicine, Inc. (NASDAQ:EDIT ) Q4 2022 Results Conference Call February 22, 2023 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O'Neill - Chief Executive Officer Michelle Robertson - Chief Financial Officer Baisong Mei - Chief Medical Officer Conference Call Participants Samantha Semenkow - Citi Dae Gon Ha - Stifel Phil Nadeau - Cowen & Company Rick Bienkowski - Cantor Fitzgerald Jay Olson - Oppenheimer Brian Cheng - JP Morgan Luca Issi - RBC Capital Markets Greg Harrison - Bank of America Yanan Zhu - Wells Fargo Gena Wang - Barclays Rich Law - Credit Suisse Liisa Bayko - Evercore ISI Operator Good morning and welcome to Editas Medicine's Fourth Quarter and Full-year 2022 Conference Call. All participants are now in a listen-only mode.

Editas Medicine, Inc. (EDIT) Q4 2022 Earnings Call Transcript

Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter

Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

They're both at the cutting edge of gene-editing technology.

These 2 Biotech Stocks Could Soar in the Next Bull Market

Exact Sciences

Which of these rebounding biotech stocks is the better buy right now?

Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?

CAMBRIDGE, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 22, 2023, at 8:00 a.m. ET to discuss results for the fourth quarter and full year of 2022 and to provide a corporate update.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update

Here is how Editas Medicine (EDIT) and Aspira (AWH) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 51.6% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Editas (EDIT) Have the Potential to Rally 51.55% as Wall Street Analysts Expect?

Exelixis

Ironwood Pharma

All three healthcare stocks are showing solid long-term potential.

3 No-Brainer Stocks to Buy Right Now for Less Than $25

Allogene Therapeutics Inc

Seagen

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

The gene-editing biotech's shares have had a strong two-week run.

Why Editas Medicine's Shares Jumped This Week

10X Genomics

CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR,  to try to improve human health.

3 CRISPR Stocks to Buy Now Or You'll Be Kicking Yourself Later

The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.

Why Editas Medicine Stock Charged Higher in January

Cellectis SA

Sangamo Therapeutics

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

7 CRISPR Stocks With the Best Long-Term Potential

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for Investors

It's been a seesaw month for the clinical-stage gene-editing biotech.

Why Shares of Editas Medicine Jumped This Week

Elevation Oncology

Fate Therapeutics

Century Therapeutics

Johnson & Johnson

Y-Mabs Therapeutics Inc

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for Investors

The mean of analysts' price targets for Editas (EDIT) points to a 72.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 72.25% Upside in Editas (EDIT): Here's What You Should Know

Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.

Editas (EDIT) Moves Ahead With its Portfolio Reprioritization

Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and  a non-exclusive license for AsCas12a

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas' iNK Cell Franchise and Related Gene Editing Technologies

Global X Genomics & Biotechnology ETF

CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material,  the Cleveland Clinic reported.

News for Editas Medicine Stock (EDIT)